Information Provided By: 
Fly News Breaks for February 28, 2020
NSRGY, AIMT
Feb 28, 2020 | 08:43 EDT
Baird analyst Brian Skorney said the Aimmune (AIMT) Q4 results were inline with expectations but more importantly, its Palforzia launch is continuing to progress. Management suggested on its conference call that current assets on hand should be sufficient to fully fund the company after their recently announced deal with Nestle (NSRGY). Skorney reiterated his Outperform rating and $64 price target on Aimmune shares.
News For AIMT;NSRGY From the Last 2 Days
NSRGY
Apr 25, 2024 | 06:12 EDT
